A5409/RAD-TB is an adaptive Phase 2 randomized, controlled, open-label, dose-ranging, platform protocol to evaluate the safety and efficacy of multidrug regimens for the treatment of adults with drug-susceptible pulmonary tuberculosis. The adaptive design allows for regimens to be added during the trial for efficient testing of new drugs and drug combinations, identified as promising via translational modeling, against the standard of care (SOC) within the same trial infrastructure.